{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:11:18Z","timestamp":1787008278497,"version":"build-2736575974"},"reference-count":40,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The thyroid eye disease (TED) treatment landscape is rapidly evolving. How new treatment options have impacted practice is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a cross-sectional electronic survey of American and European Thyroid Association members between June 2 and June 30, 2021. The survey included TED questions about resources for its management, index cases for different severities and presentations of TED, barriers for the management of TED, and participants' concerns about TED. We classified respondents into three geographic categories: North America, Europe, or other regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Two hundred fifty-two eligible participants started the survey (15% response rate), and 227 completed it. Participants were mostly men (50.2%, 114\/227), white (79.7%, 181\/227), endocrinologists with a thyroid focus (66.1%, 150\/227), practicing in a tertiary academic center (46.7%, 106\/227), caring for 10 or more TED patients over the last 12 months (40.5%, 92\/227), and reported not having a multidisciplinary TED clinic in their institution (52.8%, 120\/227). The majority reported that new TED cases per annum have not changed in the past 10 years (47.5%, 108\/227), and that TED patients are found in practice during the management of hyperthyroidism (41.8%, 95\/227). For mild active TED, participants from Europe reported a higher use of selenium (73%[96\/132] vs. 32%[20\/62] of respondents from North America and 24%[8\/33] of respondents from other regions). For moderate-to-severe active TED, there was a modest preference for teprotumumab as first-line therapy (37%, 23\/62) among North American participants and intravenous (IV) steroids (73%[96\/132], and 42%[14\/33]) for participants from Europe and other regions, respectively. These treatment preferences did not change in patients with moderate-to-severe active TED with poorly controlled diabetes. In contrast, participants from the three geographic categories preferred IV steroids for optic neuropathy and women planning pregnancy. The three top \u201cvery important\u201d concerns about TED management according to participants were: the cost of TED treatment (31.3%, 71\/227), lack of effective TED treatments (19.8%, 45\/227), and difficulty in predicting whether TED will develop (18.9%, 43\/227).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>There is a marked geographic practice variation in the management of TED. Clinicians' concerns about TED management demand ongoing research on more effective treatment, TED predictive tools, and policy changes to improve the affordability of new TED therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2022.0172","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T02:21:25Z","timestamp":1660098085000},"page":"1535-1546","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["A Survey on the Management of Thyroid Eye Disease Among American and European Thyroid Association Members"],"prefix":"10.1177","volume":"32","author":[{"given":"Juan P.","family":"Brito","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endre V.","family":"Nagy","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naykky","family":"Singh Ospina","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, University of Florida, Gainesville, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-5970","authenticated-orcid":false,"given":"Milos\u02c7","family":"Z\u02c7arkovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Belgrade, Serbia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Dosiou","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fichter","sequence":"additional","affiliation":[{"name":"ADMEDICO Orbital Centre, Olten and University Eye Department, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Lucarelli","sequence":"additional","affiliation":[{"name":"Oculoplastic, Facial Cosmetic and Orbital Surgery, Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Heged\u00fcs","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Odense University Hospital, University of Southern Denmark, Odense C, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0625-1"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066711"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje-13-0708"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje-15-0306"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3119"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2268"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000508071"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0365"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje-16-0954"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-306733"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje-09-0383"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04318.x"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje-16-0552"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00487.x"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02201"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000443828"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje-21-0479"},{"key":"e_1_3_7_21_2","unstructured":"Burch HB Perros P Bednarczuk T et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and European Thyroid Association (Under review)."},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","unstructured":"Graham JW. Missing data analysis: Making it work in the real world. Annu Rev Psychol 2009;60:549\u2013576; doi: 10.1146\/annurev.psych.58.110405.085530. PMID: 18652544.","DOI":"10.1146\/annurev.psych.58.110405.085530"},{"key":"e_1_3_7_23_2","doi-asserted-by":"crossref","unstructured":"Schafer JL Graham JW. Missing data: Our view of the state of the art. Psychol Methods 2002;7(2):147\u2013177; doi.org\/10.1037\/1082-989X.7.2.147.","DOI":"10.1037\/1082-989X.7.2.147"},{"key":"e_1_3_7_24_2","unstructured":"Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County Minnesota. Trans Am Ophthalmol Soc 1994;92:477\u2013588. PMID: 7886878; PMCID: PMC1298522."},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01479-z"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4294"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500040045034"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2012(11)18"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/01676830903047141"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.8.8768863"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199206253262603"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1998.8.653"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2802"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12688"},{"key":"e_1_3_7_35_2","unstructured":"Food Drug Administration 2020 FDA approves first treatment for thyroid eye disease. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-thyroid-eye-disease [Last accessed: December 10 2021]."},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012985"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0311-6"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-s8587(21)00056-5"},{"key":"e_1_3_7_39_2","unstructured":"Kinyoun JL. Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis). Trans Am Ophthalmol Soc 2008;106:325\u2013335. PMID: 19277244; PMCID: PMC2646429."},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(99)00057-7"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa140"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2022.0172","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2022.0172","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2022.0172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:09:26Z","timestamp":1777586966000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2022.0172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1089\/thy.2022.0172"],"URL":"https:\/\/doi.org\/10.1089\/thy.2022.0172","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}